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Introduction: Determination of programmed death ligand
1 (PD-L1) expression deﬁnes eligibility for treatment with
pembrolizumab in patients with advanced NSCLC. This
study was designed to better deﬁne which value across core
biopsy specimens from the same case more closely reﬂects
the PD-L1 expression status on whole sections and how
many core biopsy specimens are needed for conﬁdent
classiﬁcation of tumors in terms of PD-L1 expression.
Methods: We built tissue microarrays as surrogates of bi-
opsies collecting ﬁve cores per case from 268 cases and
compared PD-L1 staining results obtained by using the
validated clone SP263 with the results obtained by using
whole tumor sections.
Results: We found an overall positivity in 39% of cases at a
cutoff of 1% and in 10% of cases at a cutoff of 50%. The
maximum value across cores was associated with high
concordance between cores and whole sections and thelowest number of false-negative cases overall. To reach high
concordance with whole sections, four and three cores are
necessary at cutoffs of 1% and 50%, respectively. Impor-
tantly, with 20% as the cutoff for core biopsy specimens,
fewer than three cores showed high sensitivity and speci-
ﬁcity in identifying cases with 50% or more of tumor cells
positive for PD-L1 on whole sections. Speciﬁcally, for PD-L1Journal of Thoracic Oncology Vol. 13 No. 8: 1113-1120
1114 Munari et al Journal of Thoracic Oncology Vol. 13 No. 8expression values of 20% to 49% on cores, the probabilities
of a tumor specimen expressing PD-L1 in at least 50% of
cells on a whole section were 46% and 24% with one and
two biopsy specimens, respectively.
Conclusions: An accurate deﬁnition of the criteria to
determine the PD-L1 status of a given tumor may greatly
help in selecting those patients who could beneﬁt from
anti–programmed cell death 1/PD-L1 treatment.
 2018 International Association for the Study of Lung
Cancer. Published by Elsevier Inc. This is an open access
article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).
Keywords: PD-L1; Lung; Cancer; Heterogeneity; Biopsies
Introduction
Programmed cell death 1 (PD-1) is an inhibitory re-
ceptor that was originally identiﬁed in T lymphocytes.
Upon interaction with its ligand programmed death
ligand 1 (PD-L1), PD-1 delivers inhibitory signals that
down-regulate T-cell function. Under physiological
conditions, this interaction leads to peripheral T-cell
tolerance, whereas in patients with cancer it may impair
T-cell responses against tumor cells.1–3 In this context,
immunotherapy with checkpoint inhibitors that disrupt
PD-1–PD-L1 interaction has proved highly effective in
different tumor types, representing a true revolution in
cancer therapy.4–6
Pembrolizumab is an anti–PD-1 humanized mono-
clonal antibody that was recently granted U.S. Food and
Drug Administration approval after clinical trials con-
ducted in patients with advanced lung adenocarcinoma or
squamous cell carcinoma on the basis of PD-L1 expres-
sion on viable tumor cells, as assessed with a validated
assay. Speciﬁcally, the KEYNOTE-010 trial demonstrated
that pembrolizumab prolonged overall survival in previ-
ously treated patients whose tumors expressed PD-L1 in
at least 1% of cells.7 Moreover, the KEYNOTE-001 and the
KEYNOTE-024 trials showed signiﬁcantly longer
progression-free survival and overall survival for previ-
ously untreated patients with tumors expressing PD-L1 in
at least 50% of cells.8,9 Therefore, the immunohisto-
chemical evaluation of PD-L1 expression on tumor spec-
imens has become an issue of major importance.
However, most studies focusing on the correlation
between efﬁcacy of PD-1/PD-L1 inhibitors and expres-
sion of PD-L1 on neoplastic cells do not take into
consideration the type of material on which PD-L1
expression has been determined. In fact, such evalua-
tion can be made on the basis of biopsy specimens or
resection specimens. It is evident that PD-L1 expression
in small tissue samples such as biopsy specimens might
not be representative of the entire tumor specimen andcan display divergent results because of cancer hetero-
geneity. In this regard, by using tissue microarrays
(TMAs) as surrogates of biopsy specimens, we recently
demonstrated that discordance between core biopsy
specimens of a given tumor may occur in up to 20% and
7.9% of cases with use of cutoffs of 1% and 50% for PD-
L1–positive cells, respectively.10 To our knowledge,
harmonization studies regarding determination of PD-L1
expression between core biopsy specimens and resec-
tion specimens are still lacking.
The present study was designed to better deﬁne
which value across core biopsy specimens from the same
case more closely reﬂects the actual PD-L1 expression
status as determined on the resection specimen and the
number of biopsy specimens needed at different cutoffs
for consistent and reproducible PD-L1 quantiﬁcation
with respect to whole tumor sections, which are
considered the criterion standard.
Material and Methods
Study Cohort
The study cohort consisted of consecutive patients
with primary NSCLC who had undergone surgical
resection at the Sacro Cuore Don Calabria Hospital of
Negrar, Verona, Italy, between 2003 and 2017 and for
whom slides and parafﬁn-embedded tissue blocks were
available.
None of the patients received therapy before surgery.
Tumors were classiﬁed according to the 2015 WHO
classiﬁcation, and staging was done by using the TNM
staging manual (seventh edition). Patient demographics
and clinical data were retrieved from the digital archives.
The investigations were conducted according to the
principles expressed in the Declaration of Helsinki.
TMA Construction
For every case, all hematoxylin and eosin–stained
slides were reviewed for conﬁrmation of diagnosis; one
block was then selected for TMA construction. For each
block, ﬁve cores with a diameter of 1 mm were obtained
from diverse areas of the tumor and randomly
numbered from 1 to 5. Overall, 12 TMAs were built.
Immunohistochemistry and Scoring
From each block (single cases and TMAs) 5-mm sec-
tions were cut and stained for PD-L1 (clone SP263,
Ventana Medical Systems, Tucson, AZ) on an automated
staining platform (Benchmark Ultra [Ventana Medical
Systems]). An OptiView DAB IHC Detection Kit (Ventana
Medical Systems) and an OptiView Ampliﬁcation Kit
(Ventana Medical Systems) were used according to the
manufacturer’s recommendations for visualization of the
primary anti–PD-L1 antibody.
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HT slide scanner (Ventana Medical Systems) and scored
on the basis of percentage of tumor cells showing
membranous positivity irrespective of staining in-
tensities; a three-tiered system was then applied by us-
ing the following thresholds: less than 1%, 1% to 49%,
and at least 50%.
PD-L1 evaluation was performed blindly by two
pathologists who use clone SP263 in their clinical
practice (E.M. and G.B.); discordant cases (cores
and whole sections) were reevaluated by a third
pathologist (G.R.).
Those cores showing a neoplastic component of at
least 30% were considered adequate; therefore, cores
with lower percentages of neoplastic component were
excluded.
Macrophages were used as an internal control to
validate the adequacy of the PD-L1 staining reaction.
Statistical Analysis
Statistical analysis was carried out with Stata soft-
ware (StataCorp, College Station, TX) and R software
(version 3.2.3, R Foundation for Statistical Computing,
Vienna, Austria)11; c2 testing was used to analyze con-
tingency tables and receiver operating characteristic
curves were constructed to evaluate the predictive
ability of core biopsy samples for PD-L1 status on whole
sections. Cohen’s k was calculated for interrater
agreement.
Results
Patient Characteristics
From the initial 271 patients, three were not
considered for the analysis because of failure of TMA
construction or staining. Overall, 268 patients were
included in this study; of these, 190 (71%) were male
and 78 (29%) were female; the median age was 70 years
(range 41–87 years). The cancer of 183 of the 268 pa-
tients (68%) was diagnosed as adenocarcinoma, the
cancer of 64 patients (24%) was diagnosed as squamous
cell carcinoma, and 21 patients (8%) were determined to
have other histotypes (15 patients had large cell carci-
noma, four had adenosquamous carcinoma, and two had
large cell neuroendocrine carcinoma). The median size of
the tumors was 2.7 cm (range 0.8–21 cm).
Lymph node status was available for 246 patients:
172 patients were staged as N0, 35 as N1, 34 as N2, and
ﬁve as N3.
PD-L1 Expression and Clinicopathological
Features
Overall, PD-L1 expression value based on whole sec-
tions was negative (<1%) in 163 cases, between 1% and49% in 79 cases, and at least 50% in 26 cases, with only
one case showing homogenous positivity in 100% of cells.
We analyzed the associations between PD-L1
expression on whole sections and clinicopathological
features (Table 1). We show that with a cutoff of 1%, PD-
L1–positive tumors often corresponded to a higher stage.
Notably, squamous cell carcinomas were more often
positive than were adenocarcinomas.Interobserver Variability and Heterogeneity
of PD-L1 Expression
Regarding the evaluation of PD-L1 on whole sections,
discrepancy between the two pathologists (E.M. and
G.B.) was found in only six cases: in two cases there was
lack of concordance at a cutoff of 1% and in four cases at
a cutoff of 50% (Cohen’s k ¼ 0.98 and 0.91 at cutoffs of
1% and 50%, respectively). After consensus, one case
was deﬁned as negative (<1%), one case was scored
between 1% and 49%, and the other four cases were
scored as at least 50% positive.
In the only case that showed 100% PD-L1 positivity
on whole section, all ﬁve cores showed PD-L1 expression
in at least 50% of cells. Of the 163 cases determined to
be PD-L1–negative (<1% of stained cells) on whole
sections, only ﬁve cases showed PD-L1 expression of at
least 1% in some of the cores (one of ﬁve cores in two
cases, three of ﬁve cores in one case, and two of four
cores in two cases), with none showing positivity in
more than 5% of tumor cells. Most of the cases had all
ﬁve cores available for evaluation. In some cases, cores
were lost during processing (n ¼ 11) or contained less
than 30% tumor cells (n ¼ 72). Speciﬁcally, 215 cases
had ﬁve cores, 31 had four cores, 16 had three cores,
four had two cores, and two had one core available.
Regarding PD-L1 evaluation on the basis of cores,
lack of concordance between the two pathologists (E.M.
and G.B.) occurred in 21 cases (Cohen’s k ¼ 0.92 and
0.82 at cutoffs of 1% and 50%, respectively), for which a
third pathologist (G. R.) was required for consensus
(Supplementary Table 1).
When all cores available for each case were consid-
ered, the concordance rates within the 104 cases that
showed heterogeneity on whole sections were 93% at a
cutoff of 1% and 88% at a cutoff of 50%. Notably, once
all cases classiﬁed as negative had been eliminated, by
deﬁnition there could not be any false-positive cases.
Thus, discrepancies were due to the heterogeneous
expression of PD-L1 in neoplastic cells (Fig. 1).Deﬁnition of Best PD-L1 Value across Cores
We then compared the PD-L1 results obtained
across tissue cores for each case to establish which
value among the maximum, minimum, mean, and median
Table 1. Clinicopathological Characteristics of Patients in Relation with PD-L1 Expression on Whole Sections
Variable Overall, n (%)
PD-L1 Expression 1% PD-L1 Expression 50%
Negative, n (%) Positive, n (%) p Valuea Negative, n (%) Positive, n (%) p Valuea
Patients 268 163 (61%) 105 (39%) 242 (90%) 26 (10%)
Age
<70 y 121 (45%) 76 (63%) 45 (37%) 0.54 111 (92%) 10 (8%) 0.47
70 y 147 (55%) 87 (59%) 60 (41%) 131 (89%) 16 (11%)
Sex
Male 190 (71%) 106 (56%) 84 (44%) 0.01 170 (89%) 20 (11%) 0.48
Female 78 (29%) 57 (73%) 21 (27%) 72 (92%) 6 (8%)
Histologic type
ADC 183 (68%) 120 (66%) 63 (34%) 0.06 164 (90%) 19 (10%) 0.84
SCC 64 (24%) 33 (52%) 31 (48%) 59 (92%) 5 (8%)
Others 21 (8%) 10 (48%) 11 (52%) 19 (90%) 2 (10%)
Diameter
30 mm 164 (62%) 107 (65%) 57 (35%) 0.09b 151 (92%) 13 (8%) 0.20b
>30 mm 102 (38%) 56 (55%) 46 (45%) 89 (87%) 13 (13%)
Unk 2 0 2 2 0
N stage
N0 172 (64%) 110 (64%) 62 (36%) 0.14b 158 (92%) 14 (8%) 0.11b
N1–N3 74 (28%) 40 (54%) 34 (46%) 63 (85%) 11 (15%)
Unk 22 (8%) 13 9 21 1
aPearson chi-square test.
bFor p value, unknown cases excluded from test.
PD-L1, programmed death ligand 1; ADC, adenocarcinoma; SCC, squamous cell carcinoma; Unk, unknown.
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tained on the basis of whole sections (considered the
criterion standard).
Overall, at a cutoff of 1%, we found concordance rates
of 95.9%, 95.9%%, 86.5%, and 79.5% with the
maximum, mean, median and minimum values, respec-
tively. When a cutoff of 50% was used, we found
concordance rates of 95.6%, 96.6%, 96.2%, and 94.4%
with the maximum, mean, median, and minimum values,
respectively. In general, the maximum and mean values
appeared to better reﬂect PD-L1 expression on the
whole sections. However, because the maximum value
across cores showed the lowest number of false-negative
results for cutoffs of both 1% and 50%, only this value
was applied for subsequent analysis (Supplementary
Table 2).
Deﬁnition of Minimum Number of Biopsy
Specimens for Optimal Concordance with Whole
Sections
Table 2 summarizes the results of sensitivity, speci-
ﬁcity, and receiver operating characteristic analyses
relative to the number of cores evaluated, with the re-
sults obtained with whole sections considered to be the
reference for each case.
For cutoff of 1%, we found an area under the curve
(AUC) greater than 0.9 with three core biopsy speci-
mens; moreover, 0.91 sensitivity was reached when four
cores were considered.For cutoff of 50%, we found AUC and sensitivity
values greater than 0.9 with three cores.
We noted that at cutoff of 50%, increasing numbers
of core biopsy specimens corresponded to a decrease in
speciﬁcity (from 0.98 with one core to 0.95 with ﬁve
cores), reﬂecting the increasing number of false-positive
cases. Overall, if we considered the cases with at least
one core with PD-L1 expressed in at least 50% of cells,
the false-positive rate was 3.7% (10 cases, all with at
least four cores available) (Supplementary Table 3).
Interestingly, if we considered cases with at least two
cores with PD-L1 expressed in at least 50% of cells, the
number of false-positive results dropped from 10 to
three whereas the number of false-negative results did
not change (two cases) (Supplementary Table 4).
Importantly, at a cutoff of 50%, if we considered
fewer than three cores, sensitivity remained low
(<90%). Therefore, we evaluated the predictive value of
other PD-L1 cutoffs in core biopsy specimens, comparing
the data with that in cases in which tumor cells
expressed PD-L1 in at least 50% of cells on the whole
sections. Thus, we assessed sensitivity, speciﬁcity, and
AUC for cutoff values of 10%, 20%, 30%, and 40%
related to the number of core biopsy specimens analyzed
(Table 3). We found that at a cutoff of 20%, fewer than
three cores were sufﬁcient for identifying cases with at
least 50% of tumor cells on whole sections testing pos-
itive for PD-L1 with a sensitivity and an AUC greater
than 0.9. In particular, in the event of a single core with
Figure 1. Representative image for heterogeneity of programmed death ligand 1 (PD-L1) expression. Whole section of
squamous cell carcinoma of the lung stained with PD-L1 showing spots corresponding to tissue microarray cores numbered 1
to 5. Cores numbered 1 to 4 were sampled randomly in an area with a negative result when tested, whereas the result of
testing of core 5 was positive in more than 50% of neoplastic cells. Overall, testing of the whole tumor yielded a result of PD-
L1 expression in 20% of neoplastic cells.
August 2018 Heterogeneity of PD-L1 Expression in NSCLC 111720% to 49% of cells testing positive, the probability of
having PD-L1 expressed in at least 50% of cells on whole
section was 46%. In the event of two cores with an
expression value of 20% to 49% in one or both, the
probability of having PD-L1 expressed in at least 50% of
cells on whole section was 24% (Table 4).
Discussion
Immunotherapy with PD-1/PD-L1 axis inhibitors
represents a revolution in the ﬁeld of oncology and a
starting point for a new paradigm against cancer.5 In this
context, predicting which patients will respond
to checkpoint inhibitor therapy is a major issue that so
far has been based mainly on immunohistochemicalevaluation of PD-L1 on tumor cells. Such evaluation may
be performed both on resection specimens (when
patients experience progression after tumor resection)
and on small biopsy specimens (in the setting of
advanced tumors at diagnosis).9
Recently, the U.S. Food and Drug Administration
approved the anti–PD-1 pembrolizumab as a single agent
for patients with tumors expressing PD-L1 in at least
50% of neoplastic cells for ﬁrst-line therapy and as a
second-line therapy for patients whose tumors express
PD-L1 in at least 1% of cells.7,8
Moreover, although some studies have found signiﬁ-
cant correlation between expression of PD-L1 and
response to therapy in different tumor types,6,8,9,12,13
Table 2. Sensitivity, Speciﬁcity, and ROC AUC according to
Number of Available Cores by Cutoff
No. of Cores
by PD-L1
Expression
Cutoff Cases, n Sensitivity Speciﬁcity ROC AUC
PD-L1 1%
1 268 0.70 0.98 0.84
2 266 0.78 0.98 0.88
3 262 0.85 0.98 0.92
4 246 0.91 0.97 0.94
5 215 0.93 0.98 0.95
PD-L1 50%
1 268 0.77 0.98 0.87
2 266 0.88 0.98 0.93
3 262 0.92 0.98 0.95
4 246 0.95 0.96 0.96
5 215 0.95 0.95 0.95
ROC, receiver operating characteristic; AUC, area under the curve; PD-L1,
programmed death ligand 1.
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observed in patients whose tumors were classiﬁed as
PD-L1–negative.14,15 Such discrepancy could be due to
different factors: on the one hand, there is the intrinsic
and as-yet undiscovered biological complexity under-
pinning tumor-immunity interplay; on the other hand, it
is reasonable to think that a percentage of tumors could
be misclassiﬁed in terms of PD-L1 expression owing to
factors such as expression heterogeneity,10 different
clones, and interpathologist variability.16
Therefore, it is of major importance to determine
how many biopsy specimens should be obtained from
tumors and how to consider the results of PD-L1 staining
across them so as to maximize their reliability in pre-
dicting the true PD-L1 status of tumors and the proba-
bility of response to anti–PD-1/PD-L1 treatment.
In this study, we have addressed the question of
which value of PD-L1 expression among maximum,
mean, median, and minimum across tissue cores would
best reﬂect the actual PD-L1 expression on the entireTable 3. Sensitivity, Speciﬁcity, and ROC AUC of Different Cutof
of Cells Positive for PD-L1 on Whole Sections
No. of Cores
Cutoffs of Cells Positive for PD-L1
10% 20%
SE SP AUC SE SP
1 .96 .91 .94 .96 .95
2 .96 .88 .92 .96 .93
3 .96 .85 .91 .96 .89
4 1 .84 .92 .95 .89
5 1 .85 .92 1 .89
ROC, receiver operating characteristic; AUC, area under the curve; PD-L1, progtumor specimen and how many biopsy specimens are
necessary for optimal correlation. In addition, we have
analyzed the predictive potential of different cutoffs for
use with biopsy specimens in identifying cases with at
least 50% of tumor cells expressing PD-L1 on whole
tumor sections. To this end, we built TMAs as surrogates
of diagnostic biopsies collecting ﬁve cores for each case
from a total of 268 cases and compared the staining
results with those obtained with whole tumor sections,
which are considered the criterion standard. We found
an overall positivity in 39% of cases for a cutoff of 1%
and in 10% of cases for a cutoff of 50%. In general, the
maximum value and the mean value across cores from
each case showed the highest concordance rates with
whole sections both at a cutoff of 1% (95.9% for both
values) and at a cutoff of 50% (95.6% and 96.6%,
respectively). Moreover, we found that the maximum
value across cores correlated with the lowest number of
the overall false-negative cases (four cases and two cases
for cutoffs of 1% and 50%, respectively).
An important issue is deﬁnition of the minimum
number of biopsy specimens necessary for optimal cor-
respondence with whole tumor sections. Our results
indicate that four and three core biopsy specimens are
necessary to reach an AUC and sensitivity higher than
0.9 at cutoffs of 1% and 50%, respectively.
Importantly, with fewer than three core biopsy
specimens, the sensitivity was not satisfactory (<0.9) at
a cutoff of 50%. In this regard, we found that if we
lowered the cutoff for cores to 20%, even just one or two
cores were sufﬁcient to identify cases with PD-L1
expressed in at least 50% of tumor cells on whole sec-
tions with high sensitivity and speciﬁcity.
In the clinical context, the main concern is to avoid
missing patients who could beneﬁt from an effective
treatment and therefore keep the number of false-
negative cases as low as possible; therefore, in the
setting of a biopsy with at least 20% of tumor cells
expressing PD-L1, it could be reasonable to consider
the opportunity to repeat the bioptic procedurefs and Number of Cores in Predicting Cases with at Least 50%
30% 40%
AUC SE SP AUC SE SP AUC
.96 .88 .96 .92 .81 .97 .89
.94 .92 .95 .93 .88 .96 .92
.93 .96 .92 .94 .92 .95 .93
.92 .95 .90 .93 .95 .95 .95
.95 1 .90 .95 .95 .94 .94
rammed death ligand 1; SE, sensitivity; SP, speciﬁcity.
Table 4. Concordance between Cores with Less than 50% of
Cells Expressing PD-L1 and Whole Sections, with 20% Used
as Cutoff for Cores
No. of
cores
Whole Sections
PD-L1 Expression
<50%
PD-L1 Expression
50%
1
<20% 231 1
20%–49% 6 5
2
<20% 223 1
20%–49% 13 4
PD-L1, programmed death ligand 1.
August 2018 Heterogeneity of PD-L1 Expression in NSCLC 1119before excluding a patient for ﬁrst-line therapy with
pembrolizumab.
Because treatment with checkpoint inhibitors
(including PD-1/PD-L1 inhibitors) may cause some
toxicity, avoiding false-positive cases is also of major
importance. In this regard, it should be noted that in our
cohort at a cutoff of 50%, when at least two cores were
positive, the risk of false-positive cases dropped to 1.2%.
So far, only a few studies have addressed the issue of
PD-L1 heterogeneity and its potential role in tumor
misclassiﬁcation, given the discrepancies between bi-
opsy specimens and resection specimens.17–19 Moreover,
no attempts have been made to harmonize biopsy
specimens and resection specimens with regard to
determination of PD-L1 expression.
Kitazono et al. evaluated PD-L1 expression by using a
polyclonal antibody (4059, ProSci, Poway, CA) on 79
diagnostic biopsy specimens and corresponding surgical
specimens; they found concordance rates of 92.4% and
83.5% for cutoffs of 1% and 50%, respectively.19 In
another similar work, by evaluating PD-L1 using the
SP142 clone on 160 surgically resected samples and
paired diagnostic biopsy specimens, Ilie et al. found a
concordance rate of 81% with use of a cutoff of 1% for
tumor cells.18
These two studies18,19 differ from our study in that
the authors used diagnostic biopsy specimens; however,
the percentage of neoplastic specimens out of total bi-
opsy specimens is not clear in either of the studies. Ilie
et al.18 found a trend toward a signiﬁcant difference
between the average number of diagnostic biopsy spec-
imens in discordant versus concordant cases (3.4 versus
6.8).
Other works used TMAs as surrogate of diagnostic
biopsy specimens. Gniadek et al. evaluated PD-L1
expression on TMAs from 150 cases of NSCLC by using
SP142 antibody and an Abcam detection kit (Abcam,
Cambridge, MA); they found discrepancies among cores
in a total of 28 of 71 positive cases (40%).17 Unlike us,however, they used whole sections only in cases that
showed discordance within cores.
Recently, Li et al. evaluated PD-L1 expression on 190
resected NSCLC and matched TMA cores by using the
Dako 22C3 clone (Dako, Carpinteria, CA). At a cutoff of
1% these authors found 37% of cases to be positive, with
a discordance rate of 13.2%, whereas at a cutoff of 50%
positivity was found in 11% of cases, with a discordance
rate of 6.8%.20 Notably, these authors built their TMA by
using single cores with a diameter of 2 mm for each case;
instead, we used multiple smaller cylinders (1 mm) to
have a more comprehensive picture for each case and to
allow better computation thanks to a higher number of
cores. In addition, even with consideration of our results
on only a single core (and even though the core was
smaller), our data are in line with those of these authors
in terms of discordance rates (13% and 4.2% for cutoffs
of 1% and 50%, respectively).
In relation to general positivity at cutoffs of 1% and
50%, the results reported by Li et al.20 are similar to
ours even though two different clones were used (22C3
by Li et al. and SP263 by us).
We realize that a limitation of our study lies in its
retrospective nature and the use of TMAs as surrogates
of tumor biopsy specimens. In fact, in routine di-
agnostics, not all biopsy specimens actually correspond
to neoplastic tissue; therefore, the applicability of our
approach is possible if only neoplastic biopsy specimens
are considered. However, we believe that such approach
is informative, as the neoplastic component present in a
transbronchial biopsy that we encounter in our clinical
practice is similar in terms of quantity to the neoplastic
component present in each tissue core.
Another point is related to the issue of interobserver
variability, as was recently demonstrated in an article by
Brunnstrom et al.16; in this regard, all cores and whole
sections were evaluated blindly by two pathologists who
use SP263 in their clinical practice and discordant cases
were reevaluated by a third pathologist for consensus.
In conclusion we have demonstrated that when
evaluating multiple biopsy specimens for PD-L1 assess-
ment, the maximum value across cores should be
considered. Moreover, to reach high concordance with
whole sections, four and three core biopsy specimens are
necessary at cutoffs of 1% and 50%, respectively. In
addition, in the ﬁrst-line setting, when at least two cores
result in positive at a cutoff of 50%, the rate of false-
positive cases drops to 1.2%. Importantly, in the event
of fewer than three cores, of which at least one has at
least 20% PD-L1–positive cells, the probability of a tu-
mor with a level of PD-L1 expression of at least 50% on
the whole section is high, with sensitivity and AUC
greater than 0.9. In our view, according to our results,
pathologists should describe in their report the number
1120 Munari et al Journal of Thoracic Oncology Vol. 13 No. 8of cores analyzed and the percentage of cells positive for
PD-L1 in each one, thus allowing clinicians to make a
more conﬁdent decision with regard to patient selection
for therapy.
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